Matthew Exline is a Respiratory physician affiliated with The Ohio State University Wexner Medical Center. OpenAlex indexes 187 publications with 10,460 citations (h-index 44); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Immune Suppression and Ventilator Associated Pneumonias
Sponsor: Matthew Exline
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
71.3%Corticosteroid32.3%Symbicort30%Breo Ellipta27%Trelegy Ellipta15%Arnuity Ellipta11%Fluticasone Propionate10%Flovent Hfa7%Part D<11 patientsbeta2-Adrenergic Agonist19.4%Albuterol Sulfate Hfa100%Part D≥37 patients+ 4 more classes in this area
Metabolism & gastrointestinal
20.8%Corticosteroid13.3%Prednisone100%Part D≥23 patientsProton pump inhibitor5.1%Omeprazole100%Part D<11 patients+ 1 more class in this area
Anti-infectives
4.8%Macrolide Antimicrobial4.8%Azithromycin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2009–2013 per NIH RePORTER. The latest:
- Innate Immune System in Sepsis and Risks for Nosocomial Infections
Ohio State University
FY2013$125,825K23HL095772 - Innate Immune System in Sepsis and Risks for Nosocomial Infections
Ohio State University
FY2012$126,480K23HL095772 - Innate Immune System in Sepsis and Risks for Nosocomial Infections
Ohio State University
FY2011$127,116K23HL095772
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Pawlik, MD
The Ohio State University Wexner Medical Center
Michael Grever, MD
The Ohio State University Wexner Medical Center
Brad Rovin, MD
The Ohio State University Wexner Medical Center
Matthew Ringel, MD
The Ohio State University Wexner Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”